Latest news with #SvetlanaKobina
Business Wire
6 days ago
- Business
- Business Wire
Sarah Cannon Research Institute Announces Strategic Alliance With AbbVie to Advance Novel Cancer Therapies
NASHVILLE, Tenn.--(BUSINESS WIRE)--Today, Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, announced a strategic alliance with AbbVie. The alliance aims to accelerate the development of innovative therapies for patients with cancer through collaborative scientific engagement and operational synergies to enhance the delivery of clinical trials. "By combining SCRI's scientific and operational expertise in conducting clinical trials in the community with AbbVie's innovative drug development approach, we can further strengthen our mission to advance novel therapies for patients," said Dee Anna Smith, Chief Executive Officer, SCRI. "Working together, we can expedite the development of more treatment options and transform clinical trial delivery, providing greater access to cutting-edge therapies for patients close to home.' SCRI's research network brings together more than 1,300 physicians who are enrolling patients to clinical trials at over 200 locations in more than 20 states across the U.S. Through the alliance, SCRI and AbbVie will enhance scientific connectivity, enabling collaboration with SCRI's physician leadership and contract research organization, SCRI Development Innovations, to drive clinical development. 'We are encouraged about the opportunity to establish a strategic scientific alliance with SCRI as we work together on initiatives aimed to address high unmet needs for patients battling cancer," said Svetlana Kobina, MD., PhD., Vice President of AbbVie Oncology, Global Medical Affairs. "Through close collaboration with SCRI and its community sites, we hope to gain a more comprehensive understanding of the treatment paths and health needs of patients living with cancer to provide tailored, patient-centered scientific solutions. This partnership enables us to delve deeper into the challenges faced by medical oncologists, hematologists, patients and caregivers to help us design clinical studies that more accurately represent all patient communities.' The collaboration will leverage SCRI's advanced research operational capabilities through its Accelero model, which maximizes site contributions, optimizes site activation timelines, and synchronizes end-to-end clinical research management. The Accelero model utilizes SCRI's robust Personalized Medicine program, including centralized screening services to enable more seamless identification and enrollment of patients on studies. Additionally, through SCRI's streamlined data delivery solutions, SCRI can ensure timely access to data to inform drug development and optimize clinical trial delivery. About Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is one of the world's leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI's research network brings together more than 1,300 physicians who are enrolling patients to clinical trials at over 200 locations in more than 20 states across the U.S. Visit to learn more.
Yahoo
17-03-2025
- Business
- Yahoo
AbbVie reports final analysis from Phase III trial of Elahere for ovarian cancer
US-based pharmaceutical company AbbVie has reported the final analysis from the Phase III MIRASOL trial, which assessed its antibody-drug conjugate (ADC) Elahere against chemotherapy for treating platinum-resistant ovarian cancer (PROC). The randomised trial assessed the therapy's safety and efficacy when given to women with folate receptor alpha (FRα) positive PROC. Its primary endpoint was progression-free survival (PFS), with its secondary endpoints being objective response rate (ORR) and overall survival (OS). The study enrolled 453 subjects who had received up to three previous therapies and exhibited high-grade serous epithelial PROC expressing high FRα levels. The median follow-up of 30.5 months showed that ADC treatment led to a median PFS of 5.59 months compared to 3.98 months for investigator's choice (IC) chemotherapy, decreasing the tumour progression or mortality risk by 37%. In addition, it achieved an ORR of 41.9%, significantly higher than the 15.9% achieved with chemotherapy. Subjects treated with Elahere also experienced a superior median OS of 16.85 months against 13.34 months for those receiving IC chemotherapy, marking a 32% decrease in mortality risk. The drug's safety profile and duration of response were consistent with the primary data analysis at a median follow-up of 13.1 months. AbbVie oncology medical affairs vice-president Svetlana Kobina said: "Ovarian cancer can be devastating, and when cancer cells stop responding to chemotherapy patients may feel hopeless about their journey. 'The data presented today reinforce the importance of Elahere as a transformative therapy for patients with limited options.' Elahere received full approval from the US Food and Drug Administration in March 2024 and from the European Commission last November. Several other nations are currently reviewing applications for marketing authorisation submitted by AbbVie for the drug. Last June, AbbVie released positive topline data from the Phase II PICCOLO trial, which investigated Elahere as a single agent in heavily pre-treated platinum-sensitive ovarian cancer subjects. "AbbVie reports final analysis from Phase III trial of Elahere for ovarian cancer" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
